DexCom, Inc. (DXCM) Stock

Understand DexCom, Inc.: how it makes money

DexCom makes continuous glucose monitoring (CGM) systems for people with diabetes and for healthcare providers, and it also sells its Real-Time API to enable integration of CGM data into third-party digital health applications and devices.

DexCom's profit model is primarily driven by how many active CGM customers it has (Global Active Customer Base, G-Series and D-Series), and how reliably it can deliver replacement systems on time (Replacement System Timing Rate), because CGM systems require ongoing replacement consumption rather than one-time sales.

Business quality (Solid): The company highlights operating measures tied to its installed base (Global Active Customer Base) and operational execution (on-time shipping and replacement timing), which are directly connected to ongoing CGM usage.

Valuation: At 32× earnings, DXCM trades in line with the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

• Large and trackable installed base: DexCom reports a Global Active Customer Base (G-Series and D-Series) of 2.8 million, giving investors an operating read on how many CGM users it is supporting.
• Execution metrics support repeat usage: The reported Replacement System Timing Rate is 99.9 percent, which is an important operational factor for ongoing CGM replacement demand.
• Broader market access signals continued adoption: DexCom reports Continuous Glucose Monitoring Penetration Into Covered Lives of 30 percent, and it also reports Pharmacy Copay Coverage With Zero Copay Share (Dexcom Commercial Users) of 30 percent.

Bear case

• Revenue is still tied to geographic mix: In the latest reporting, revenue is concentrated between the United States (0.83B) and International (0.36B), so weaker growth or policy or market changes in either area could impact results.
• New initiatives appear smaller so far: Stelo revenue is 0.1B, with Stello app downloads of 400,000 and Stello users, first four months after launch of 140,000, indicating early scale relative to the broader CGM business.
• Reported performance can still be sensitive to manufacturing and fulfillment: If On-Time Shipping Rate for Commercial Orders and Replacement System Timing Rate were to deteriorate from current levels, repeat purchase behavior could be affected.

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

• Boston Scientific Corporation (BSX)
• Becton, Dickinson and Company (BDX)
• ResMed Inc. (RMD)
• Medline Inc. (MDLN)
• West Pharmaceutical Services, Inc. (WST)
• Solventum Corporation (SOLV)
• Baxter International Inc. (BAX)
• Penumbra, Inc. (PEN)